Status: Recruiting
ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis
This study will evaluate the safety and efficacy of ATSN-201 in subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).
Participants needed: 97
Trial details
Phase: Phase 3Age: 6+Biological sex: AllType: InterventionalSponsor: Atsena Therapeutics Inc.Updated: Apr 30, 2026Locations: 4
Eligibility criteria
Age ≥ 18 for Cohorts 1 through 4, and age ≥ 6 years and < 18 years for Cohort 5. [+3]
Pre-existing eye conditions in the study eye that would contribute significantly... [+12]